Pfizer Can't Derail EpiPen Pay-For-Delay Discovery: 2nd Circ.
The Second Circuit on Tuesday rejected Pfizer Inc.'s effort to shield evidence of a suspected pay-for-delay deal involving emergency allergy treatment EpiPen, saying the drugmaker can't torpedo a New York discovery...To view the full article, register now.
Already a subscriber? Click here to view full article